Sun Pharmaceutical Industries experienced a significant decline in net profit during the September quarter of FY27. The company incurred acquisition-related costs of Rs 346.16 crore while preparing for the Organon acquisition. Revenue from operations increased by 11.9% compared to the same quarter last year. An important settlement of Rs 922.67 crore was reached concerning a litigation in the US. The...
Sun Pharma books Rs 346 crore Organon deal costs in Q2; profit falls 36%
Sun Pharmaceutical Industries experienced a significant decline in net profit during the September quarter of FY27. The ...
By Dhallo News · October 30, 2026 at 2:57 PM IST
Source: Economic Times - Banking & Finance
SOURCE: Economic Times - Banking & Finance
ORIGINAL REPORT: Click here
DHALLO EDITORIAL STATUS: Aggregated & reviewed
Have feedback on this article?Report error or suggestion
